Allianz Asset Management
ACOR

Allianz Asset Management’s Acorda Therapeutics ACOR Stock Holding History

Allianz Asset Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-547
Closed -$1.55M – 2770
2017
Q3 		$1.55M Buy
547
+64
+13% +$169K ﹤0.01% 2095
2017
Q2 		$1.14M Buy
+483
New +$957K ﹤0.01% 2168
2014
Q3 		– Sell
-263
Closed -$1.06M – 2384
2014
Q2 		$1.06M Sell
263
-819
-76% -$3.34M ﹤0.01% 1378
2014
Q1 		$4.92M Buy
1,082
+179
+20% +$724K 0.01% 960
2013
Q4 		$3.16M Buy
903
+820
+988% +$3.2M ﹤0.01% 1071
2013
Q3 		$342K Buy
83
+29
+54% +$125K ﹤0.01% 1588
2013
Q2 		$214K Buy
+54
New +$222K ﹤0.01% 1619

Other funds holding ACOR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Allianz Asset Management's ACOR Position: Q4 2017 in Review

Allianz Asset Management sold out of Acorda Therapeutics (ACOR) in Q4 2017, closing a stake of 547 shares — an estimated $1.55M sold.

Allianz Asset Management first reported a position in ACOR in Q2 2013 and held it in 7 quarters. The position peaked at $4.92M in Q1 2014. 150 funds tracked by Wall St. Rank hold ACOR as of Q4 2017.

  • Allianz Asset Management reported no remaining Acorda Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Allianz Asset Management sold 547 Acorda Therapeutics shares in Q4 2017, an estimated $1.55M.
  • Allianz Asset Management first reported a position in Acorda Therapeutics in Q2 2013 and held it in 7 quarters.
  • Allianz Asset Management's Acorda Therapeutics position peaked at $4.92M in Q1 2014.
  • 150 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2017.

Based on Allianz Asset Management's 13F filing for Q4 2017, filed 13 Feb 2018.